Cadila-CSIR's sepsis drug shows promise in fight against Covid-19

As the race to find treatment or vaccine for Covid-19 hots up, Ahmedabad-based Cadila Pharmaceuticals and the Council of Scientific and Industrial Research’s (CSIR’s) Sepsivac is all set to enter Phase 3 clinical trials after the earlier phase showed positive results. 

The public-private partnership trial-generated data will be soon presented before the country’s drug regulator to see if it can get emergency-use authorisation. 

“By July 15, we will have the necessary data from the Phase 2 trials and again approach the regulator to see if this drug can be given emergency-use authorisation in the wake of the pandemic. Meanwhile, we also have